Supplementary Table 1. Univariate analysis for prognostic factors.

Variable	Group	PFS	OS	Objective response (PR)
Gender	M F	HR – 0.45; 95% CI: 0.13–1.50, p = 0.19	HR – 1.5; 95% CI: 0.27–8.48, p = 0.49	-
ECOG PS	0–1 2–4	HR – 2.21; 95% CI: 0.76–6.40, p = 0.12	HR – 3.2; 95% CI: 0.87–12.48, p = 0.70	-
Primary site	Extremity Non-extremity	HR – 1.54; 95% CI: 0.35–6.68, p = 0.33	HR – 2.5; 95% CI: 0.37–16.84, p = 0.60	-
S.Albumin	<3.5 g/dL ≥3.5 g/dL	HR – 6.0; 95% CI: 0.81–43.9, p = 0.07	HR – 2.3; 95% CI: 1.12–7.82, p = 0.005	-
Haemoglobin	<10g/dL =≥10 g/dL	HR – 0.43; 95% CI: 0.10–1.75, p = 0.25	HR – 0.18; 95% CI: 0.01–2.10, p = 0.15	-
Pazopanib starting dose	400 mg/600 mg 800 mg	HR – 1.2; 95% CI: 0.33–4.32, p = 0.90	HR – 1.83; 95% CI 0.27–12.1, p = 0.33	HR – 7.0; 95% CI: 0.86–56.8, p = 0.069
Previous lines of therapy	<2 ≥2	HR – 0.88; 95% CI: 0.30–2.60, p = 0.82	HR – 1.52; 95% CI: 0.16–14.13, p = 0.7	-

M, Male; F, Female; ECOG PS, Eastern Cooperative Oncology Group Performance Status; PFS, Progression-free survival; OS, Overall survival; PR, Partial response; HR, Hazard ratio; CI, Confidence interval